Subscribe To

Price Alert Latest News Economic Calendar News

OCX / OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call Participants Mike Matson - Needham & Co. Operator Welcome to the OncoCyte Q2 2023 Earnings Call. All participants will be in listen-only mode. Read More

Demo Live Account See Partner Details

Content Topics

Oncocyte

Corporation

OCX

2023

Earnings

Call

Transcript

Stock

Posted: Aug 10 2023, 12:06

Author Name: Seeking Alpha

OCX News

By Seeking Alpha
August 10, 2023

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, I

By GlobeNewsWire
April 27, 2023

Oncocyte To Announce First Quarter 2023 Financial Results

IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will

By 24/7 Wall Street
April 10, 2023

Broadwood Partners Now Owns 33.3% of OncoCyte

Fintel reports that Broadwood Partners has filed a 13D/A form with the SEC disclosing ownership of 57.13MM shares of OncoCyte Corp (OCX).

By Market Watch
December 16, 2022

Oncocyte cuts 40% of staff

Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would r

By Seeking Alpha
November 10, 2022

OncoCyte Corporation (OCX) Q3 2022 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relati

By Seeking Alpha
August 11, 2022

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q2 2022 Results - Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Caroline Corner - Westwicke, Inves

By Zacks Investment Research
July 15, 2022

OncoCyte (OCX) Upgraded to Buy: Here's What You Should Know

OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

By Seeking Alpha
May 11, 2022

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q1 2022 Results - Earning Calls Transcript

OncoCyte Corporation (NASDAQ:OCX ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ronnie Andrews – President and Chie

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.